Title

Naproxen Sodium Extended-Release Actual Use Study
An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Indication/Condition

    Pain
  • Intervention/Treatment

    naproxen ...
  • Study Participants

    497
The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.
Issues on adverse event data are addressed in the Adverse Event section.

The following acronyms and abbreviations were used in the results section.

- General Educational Development (GED)
Study Started
Jul 31
2008
Primary Completion
Nov 30
2008
Study Completion
Nov 30
2008
Results Posted
May 17
2011
Estimate
Last Update
Aug 25
2015
Estimate

Drug Naproxen Sodium ER (BAYH6689)

Consumer use of Extended Release Naproxen Sodium

Naproxen Sodium ER (BAYH6689) Experimental

subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever

Criteria

Inclusion Criteria:

Self report use of Over The Counter (OTC) analgesics
Able to read and understand English
Provide written informed consent (subjects 12- 17 years of age provide written as sent and/ or parent or legal guardian provide written consent)
Purchase the investigational product

Exclusion Criteria:

Have participated in a study involving OTC analgesics in the last 12 months
They or someone else in the household work for a market research company, an advertising agency, a public relations firm, pharmaceutical company, as a healthcare professional, or as part of a health care practice
Have a history of known allergies to nonsteroidal anti-inflammatory drugs (NSAIDs) (i.e., Naproxen, Ibuprofen, etc) or Aspirin
Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
(Female subjects) are pregnant or breastfeeding

Summary

Naproxen Sodium ER (BAYH6689)

All Events

Event Type Organ System Event Term Naproxen Sodium ER (BAYH6689)

Use Days With One or More Misuse Occasions

Misuse occasion: any reported use of 2 or more tablets within a 22 hour period (included use of 2 tablets in 1 dose or the use of 1 tablet at one time and 1+ tablets at a later time within the same 22 hour period). Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in 1 use-day. If a subject reported product consumption on 3 different days this resulted in 3 use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.

Naproxen Sodium ER (BAYH6689)

use days with a misuse occasion

294.0
days

use days without a misuse occasion

2112.0
days

Dosing Occasions With One and More Than One Tablet Taken

Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

Naproxen Sodium ER (BAYH6689)

more than one tablet taken

66.0
dosing occasions

only one tablet taken

2500.0
dosing occasions

Use Days With and Without Next Dose Less Than 22 Hours Later

Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in one use-day. If a subject reported product consumption on three different days this resulted in three use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.

Naproxen Sodium ER (BAYH6689)

at least one dose less than 22 hours later

231.0
days

no dose less than 22 hours later

2175.0
days

Number of Subjects With and Without More Than One Tablet Taken Per Dose

Naproxen Sodium ER (BAYH6689)

never took more than one tablet per dose

440.0
participants

took more than one tablet per dose

27.0
participants

Number of Subjects With and Without Next Dose Less Than 22 Hours Later

This Outcome is a measure of subjects while Outcome Measure 3 provides the outcome as a measure of cumulative number of use-days for all subjects involved.

Naproxen Sodium ER (BAYH6689)

at least one dose less than 22 hours later

108.0
participants

no doses less than 22 hours later

359.0
participants

Number of Subjects With and Without More Than 660 mg at Least Once

This measure refers to number of subjects that exceeded 660 mg of naproxen sodium per day at least once during the reporting period. The maximum dose (660 mg) may have been exceeded with one dose (if a subject consumed two tablets in one dosing occasion) or may have been exceeded throughout the course of a use-day (if a subject took one tablet in one dosing occasion and then later in the same day took one or more tablets in another dosing occasion).

Naproxen Sodium ER (BAYH6689)

more than 660 mg at least once

123.0
participants

not more than 660 mg

344.0
participants

Number of Subjects That Have Taken Study Drug on More Than 10 Consecutive Days and Not on More Than 10 Consecutive Days

This measure is reporting how many subjects exceeded the label limit for consecutive days of study drug dosing

Naproxen Sodium ER (BAYH6689)

more than 10 consecutive days

109.0
participants

not more than 10 consecutive days

376.0
participants

Number of Total Dosing Occasions Per Subject

Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

Naproxen Sodium ER (BAYH6689)

5.5
dosing occasions (Mean)
Standard Deviation: 3.7

Average Daily Dose

Naproxen Sodium ER (BAYH6689)

722.0
mg (Mean)
Standard Deviation: 233.4

Number of Dosing Occasions Per Subject That Exceeded 660 mg

Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

Naproxen Sodium ER (BAYH6689)

0.6
dosing occasions (Mean)
Standard Deviation: 1.6

Age, Continuous

49.8
years (Mean)
Standard Deviation: 15.1

Education

Literacy

Prior Analgesic Use

Race

Sex: Female, Male

Overall Study

Naproxen Sodium ER (BAYH6689)

Drop/Withdrawal Reasons

Naproxen Sodium ER (BAYH6689)